Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding Cardinal Health’s opioid reserve details or segment margin shifts inside a 300-page filing can feel impossible. Cardinal Health’s SEC disclosures span distribution economics, medical-surgical inventory turns, and litigation footnotes that challenge even seasoned analysts.
Stock Titan turns that problem on its head. Our AI-powered summaries transform the Cardinal Health annual report 10-K simplified, break down every Cardinal Health quarterly earnings report 10-Q filing, and flag material changes in plain language. Real-time alerts push Cardinal Health Form 4 insider transactions to your dashboard the moment they hit EDGAR, so you never miss executive stock moves.
Whether you’re looking for Cardinal Health insider trading Form 4 transactions, a quick read on an unexpected 8-K material event explained, or need the numbers behind last quarter’s distribution margin in seconds, our platform delivers:
- AI-generated highlights that answer “What changed and why?”
- Side-by-side trend views for revenue, cash flow, and litigation accruals
- Clickable access to every filing type—from proxy statement executive compensation tables to shelf registrations
Spend less time decoding footnotes and more time acting on insights. Stock Titan provides Cardinal Health SEC filings explained simply, complete with earnings report filing analysis and Cardinal Health executive stock transactions Form 4 feeds. Understand Cardinal Health SEC documents with AI—without wading through hundreds of pages.
Jessica L. Mayer, Chief Legal/Compliance Officer of Cardinal Health (CAH), reported an acquisition of equity tied to performance awards. The Form 4 shows a transaction dated 08/12/2025 in which 49,994 common-share equivalents were recorded as acquired; the filing explains these are performance share units that will settle on 08/15/2025. The reported price is $0, consistent with a compensatory grant rather than a market purchase. After the reported transaction, Ms. Mayer's beneficial ownership is listed as 105,104 common shares.
This disclosure documents an executive equity grant converting to common shares on settlement and updates insider holdings for regulatory transparency. Table II contains no derivative transactions; the entry is limited to the performance-share settlement described in the explanation.
Stephen M. Mason, an officer of Cardinal Health, Inc. (CAH), reported a non-cash acquisition on 08/12/2025. The filing shows 54,537 performance share units acquired that, per the explanatory note, will settle into common shares on August 15, 2025 at an effective price of $0. After this award, the report lists 89,514 shares beneficially owned following the transaction. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, James E. Barnett, on 08/12/2025. The filing identifies the reporting person as an officer with title shown as CEO, GMPD Segment.
Jason M. Hollar, identified as Chief Executive Officer, filed a Form 4 for Cardinal Health, Inc. (CAH) reporting a transaction dated 08/12/2025. The filing shows an acquisition of 245,420 common shares recorded as performance share units that the filer states will settle on August 15, 2025. The reported price is $0 and the filing lists 437,235 shares beneficially owned following the reported transaction. The form is signed by James E. Barnett, Attorney-in-fact on 08/12/2025.
Cardinal Health Chief Financial Officer Aaron E. Alt reported a change in beneficial ownership on 08/12/2025. The Form 4 shows an acquisition of 67,448 common shares through performance share units that are stated to settle on August 15, 2025, with a reported transaction price of $0 (reflecting award settlement). Following the reported transaction, the filing lists total beneficial ownership of 102,396 shares. The filing was executed by an attorney-in-fact and contains an explanatory remark that the shares reflect performance share units.
Cardinal Health filed a Form S-3 shelf prospectus dated August 12, 2025 that permits the company to offer, from time to time, Class A common shares, preferred shares, unsecured debt securities, units or any combination of these securities; prospectus supplements will specify terms for each offering. The company is a well-known seasoned issuer and its common shares trade on the NYSE under the symbol CAH.
The Articles authorize up to 750 million common shares; as of June 30, 2025 approximately 271 million common shares were issued and about 32 million were held in treasury. The Articles also authorize 5 million Class B common shares (none outstanding) and 500,000 preferred non-voting shares (none outstanding).
The prospectus incorporates Cardinal Health’s Annual Report for the fiscal year ended June 30, 2025 and enumerates material risks including opioid-related litigation and a U.S. DOJ review of anti-diversion practices, the Company’s Corporate Integrity Agreement, EtO sterilization regulatory and litigation risks, high sales concentration with CVS Health, supply chain and tariff uncertainties, and commodity cost pressures. Net proceeds are intended for general corporate purposes.
Cardinal Health reported consolidated revenue of $222.6 billion for fiscal 2025, down 2% from the prior year largely because key Pharma distribution contracts with OptumRx expired (OptumRx accounted for 17% of consolidated revenue in fiscal 2024). Despite lower revenue, GAAP operating earnings rose 83% to $2.3 billion and GAAP diluted EPS increased 87% to $6.45, while non-GAAP operating earnings rose 15% to $2.8 billion and non-GAAP diluted EPS was $8.24, reflecting stronger branded and specialty pharmaceutical contributions and results from newly acquired MSO and at-home businesses.
The company deployed $5.3 billion for acquisitions in fiscal 2025, completed major transactions including a 73% interest in GI Alliance (~$2.8 billion), ADS ($1.1 billion), and ION ($1.1 billion), and recognized higher acquisition-related amortization and costs. Cash and equivalents fell to $3.9 billion, long-term obligations were $8.5 billion, and an opioid litigation accrual totaled $4.9 billion, while interest expense increased to $215 million due to new debt financing.
Cardinal Health, Inc. disclosed that it has issued a news release reporting results for the quarter and fiscal year ended June 30, 2025. The company has scheduled a management webcast where the CEO and CFO will discuss those results and provide commentary on the outlook for the fiscal year ending June 30, 2026. The slide presentation and an audio replay will be available on the company’s Investors page.
The filing also reports that The Specialty Alliance, Cardinal Health’s multi-specialty management services organization, has entered into a definitive agreement to acquire Solaris Health. The two news releases are furnished as exhibits to the report.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
